Imunon, Inc. IMNN
Last close
1.58
2026-09-04
Market cap
$8.9M
2026-06-30 share count
52-week range
1.47 - 6.03
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-6.83
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | — |
| R&D | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M |
| SG&A | $6.9M | $7.5M | $9.7M | $13.7M | $10.9M | $7.6M | $8.0M | $9.7M | $5.9M | $6.5M |
| Total operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M | $19.0M | $21.1M | $21.6M | $19.0M | $21.1M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M | -$18.5M | -$20.6M | -$21.1M | -$18.5M | -$20.6M |
| Interest expense | — | — | $197.1K | $5.0M | $569.9K | $1.3M | — | — | — | — |
| Pre-tax income | $14.5M | $18.6M | -$20.8M | -$37.5M | -$22.2M | -$23.3M | -$18.7M | -$22.3M | -$20.4M | — |
| Income tax | — | — | $1.3M | $1.6M | $1.4M | $1.8M | $1.8M | $10.4M | — | — |
| Net income | $14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M | -$21.5M | -$16.9M | -$11.9M | -$20.4M | -$22.1M |
| EPS, basic | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 | — | — | — | — | — |
| EPS, diluted | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 | -10.08 | -0.77 | -0.68 | -2.72 | -11.89 |
| Shares, diluted (wtd. avg.) | $2.1M | $1.1M | $9.0M | $7.1M | $5.4M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.8M | $5.9M | $5.8M | $11.5M | $19.6M | $17.2M | $6.9M | $13.4M | $11.4M | $2.6M |
| Short-term investments | — | — | $9.9M | $21.2M | $29.8M | — | $7.9M | $14.2M | $12.7M | $1.7M |
| Total current assets | $10.7M | $8.0M | $18.2M | $36.8M | $51.9M | $18.8M | $16.2M | $28.1M | $24.3M | $4.5M |
| Property, plant and equipment | $529.9K | $541.3K | $751.9K | $548.3K | $477.0K | $294.6K | $405.4K | $184.6K | $175.8K | $462.8K |
| Goodwill | — | — | — | — | — | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Other intangibles | — | — | — | — | — | $113.7K | $341.0K | $568.3K | $795.6K | $1.0M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M | $37.5M | $38.3M | $46.9M | $47.5M | $30.8M |
| Accounts payable | — | — | $3.5M | $3.6M | $2.5M | $2.2M | $2.9M | $3.0M | $3.4M | $2.9M |
| Total current liabilities | $4.6M | $4.8M | $7.4M | $10.0M | $6.8M | $6.8M | $7.9M | $6.1M | $6.2M | $8.4M |
| Long-term debt | — | — | — | $6.0M | $5.9M | $5.1M | $9.8M | $9.4M | — | — |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M | $18.9M | $23.7M | $26.0M | $20.8M | $24.1M |
| Retained earnings | -$421.3M | -$406.8M | -$388.2M | -$368.7M | -$332.8M | -$312.0M | -$290.5M | -$273.7M | -$261.8M | -$241.4M |
| Total equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M | $18.6M | $14.6M | $20.9M | $26.7M | $6.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M | -$15.6M | -$20.3M | -$7.0M | -$16.6M | -$18.4M |
| Depreciation and amortisation | $291.9K | $240.2K | $248.2K | $196.5K | $702.9K | $741.5K | $721.7K | $356.9K | $553.0K | $1.0M |
| Stock-based compensation | $127.4K | $477.3K | $759.0K | $2.7M | $3.8M | $1.9M | $2.3M | $4.6M | $1.1M | $1.5M |
| Capital expenditure | $280.6K | $29.5K | $451.8K | $267.8K | $311.6K | $19.1K | $349.2K | $138.4K | $38.6K | $62.5K |
| Investing cash flow | -$280.6K | $9.8M | $11.0M | $8.3M | -$30.1M | $7.9M | $5.9M | -$1.6M | -$11.0M | $9.1M |
| Financing cash flow | $17.1M | $9.1M | -$3.6M | $6.7M | $54.8M | $18.0M | $7.8M | $10.6M | $36.5M | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020999.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |